Board of Directors

Sandeep Laumas, M.D.
Executive Chairman
Sandeep Laumas
Dr. Laumas founded Bearing Circle Capital and has served as its Managing Director since August 2007. Dr. Laumas began his career at Goldman Sachs & Co. in 1996 as an equity analyst in the healthcare investment banking division working on mergers, acquisitions and corporate finance transactions before transitioning to the healthcare equity research division. After leaving Goldman Sachs in 2000, Dr. Laumas moved to the buyside as an analyst at Balyasny Asset Management from 2001 to 2003. Dr. Laumas was a Managing Director of North Sound Capital from 2003 to 2007, where he was responsible for the global healthcare investment portfolio. Dr. Laumas serves as an independent director on the board of directors of Bioxcel Therapeutics, Inc. (NASDAQ: BTAI) since August 2017.  He also served on the board of directors of SRL Pvt. Ltd., one of southeast asia’s largest clinical laboratory service company from February 2011-2012 and a member of the board of director of Parkway Holdings Ltd. (Singapore) (acquired by IHH Healthcare for $3 Billion: SGX: IHH) from May to August 2010. Dr. Laumas received his A.B. in Chemistry from Cornell University in 1990, M.D. from Albany Medical College in 1995 with a research gap year at the Dana-Farber Cancer Institute and completed his medical internship in 1996 from the Yale University School of Medicine.
Chairman of the Board
Christopher P. Prior, Ph.D.
Chief Executive Officer
Christopher P. Prior
Dr. Prior is a recognized industry leader both as a developer of important new therapeutics and as an accomplished serial entrepreneur. Over the course of his 30-year career, he has generated more than 25 INDs and achieved four product approvals. In addition, he founded, built-up and sold two companies (Principia, BioRexis) in deal values exceeding $0.5 Billion. Chris joined Innovate in 2015 as Chief Executive Officer. Chris received a B.Sc. (honors) in chemistry from the University of London, a Ph.D. in biochemistry from Columbia University in New York City and a research fellowship at The Rockefeller Medical Institute (New York). Chris is a member of the New York Academy of Sciences and is the author of numerous publications and patents focused on the development of therapeutics.
Jay P. Madan, M.S.
Founder, President and Chief Business Officer
Jay P. Madan
Mr. Madan founded Innovate Biopharmaceuticals in 2013 and has spent more than two decades in life sciences/biotech as a leader in M&A, technology transfer, cross border licensing and project development.  Mr. Madan’s experience in working across multiple teams at Reliance Life Sciences, Millipore, Baxter, Dade Behring, and Goodwin led him to develop a global network of healthcare professionals. He was the VP of Business Development at Reliance Biopharmaceuticals Pvt. Ltd. part of Reliance Industries Ltd., India’s largest conglomerate. Both at Reliance and Goodwin, he was focused on the development of their contract manufacturing businesses. Mr. Madan holds a Bachelor of Chemical Engineering from University of Mumbai and an M.S. in Chemical Engineering from Washington State University.
Financial Expert
Lorin K. Johnson, Ph.D.
Lorin K. Johnson

Lorin K. Johnson, Ph.D. Dr. Johnson joined Innovate’s board of directors in January 2018. He is the founder and Chief Scientist of Glycyx PharmaVentures Ltd., a biopharma investment and development company. In 1989, he co-founded Salix Pharmaceuticals, Inc. (Nasdaq: SLXP), a specialty pharmaceutical company, and held senior leadership positions prior to its $15.8 billion acquisition by Valeant Pharmaceuticals International, Inc. (NYSEA: VRX) in April 2015. Prior to Salix, Dr. Johnson served as Director of Scientific Operations and Chief Scientist at Scios, Inc. (formerly California Biotechnology, Inc). He is a board member of Glycyx MOR, Ltd. and Kinisi Therapeutics, Ltd., both GI specialty pharma companies based on the Isle of Man, Intact Inc., a GI specialty drug delivery company based in Belmont, CA, and Tumour Trace Ltd, a cancer diagnostic company based in Nottingham, UK. In addition to his career in industry, Dr. Johnson has served as an Assistant Professor of Pathology at Stanford University Medical Center and held academic positions at Stanford University School of Medicine and the University of California, San Francisco. He is the co-author of 75 journal articles and book chapters and is the coinventor on 22 issued patents. Dr. Johnson holds a Ph.D. from the University of Southern California and was a Postdoctoral Fellow at the University of California, San Francisco.

Independent Director
Anthony E. Maida III, PhD, MA, MBA
Anthony E. Maida III

For 25 years, Dr. Maida has focused on the clinical development of immunotherapies to treat patients with cancer.

Dr. Maida is currently Senior Vice President – Clinical Research for Northwest Biotherapeutics, Inc., a cancer vaccine company focused on therapy of patients with glioblastoma multiforme and prostate cancer. Dr. Maida was formerly Vice President of Clinical Research and General Manager, Oncology, World-wide for PharmaNet, Inc. Prior to coming to Pharmanet, Dr. Maida served as Chairman, Founder and Director of BioConsul Drug Development Corporation and Principal of Anthony Maida Consulting International, servicing pharmaceutical firms, venture capital, hedge funds and Wall Street, in the clinical development of therapeutic products and product/company acquisitions.

Over the past 18 years Dr. Maida has served in a number of executive roles, including, Chairman, CEO, COO, CSO, CFO and business development. Dr. Maida was formerly the President and CEO of Replicon NeuroTherapeutics, Inc., a biopharmaceutical company focused on the therapy of patients with tumors (both primary and metastatic) of the CNS.

Prior to Replicon Dr. Maida served as Interim CEO for Trellis Bioscience, Inc. In 2000 Dr. Maida served as President of CancerVax Corporation. Over recent years Dr. Maida has raised, or assisted in financings, in excess of $200 million for start-up and emerging biotechnology companies. Dr. Maida was President and Chief Executive Officer of Jenner Biotherapies, Inc., and has served as Vice President of Finance and CFO for Lockheed DataPlan, a wholly owned subsidiary, and Senior Financial Controller of Lockheed Missiles, a $1.7 billion division, of Lockheed Missiles and Space Company.

Dr. Maida serves or has served on the advisory board of EndPoint BioCapital, Sdn Bhd (Kuala Lumpur, Malaysia), and as an advisor, consultant and technical analyst for CMX Capital, LLC, Sagamore Bioventures, Roaring Fork Capital, Toucan Capital, North Sound Capital, The Bonnie J. Addario Lung Cancer Foundation and Pediatric BioScience, Inc.

Dr. Maida holds a B.A. degree in Biology, a B.A. Degree in History, a MBA, a MA in toxicology and a Ph.D. in Immunology. He is a member of the American Society of Clinical Oncology (ASCO), the American Association for Cancer Research (AACR), the Society of Neuro-Oncology (SNO), the International Society for Biological Therapy of Cancer (iSBTc) and the American Chemical Society. Dr. Maida holds a number of patents and patent applications associated with various therapeutic modalities and approaches.

Independent Director
Roy Proujansky, MD
Roy Proujansky

He received his undergraduate degree and his medical degree from Northwestern University in Chicago. He subsequently trained in Pediatrics at the University of Connecticut. Dr. Proujansky completed a Clinical and Research fellowship in the Combined Program in Gastroenterology and Nutrition at the Children’s Hospital, Massachusetts General Hospital, Harvard Medical School and a Research Fellowship in Infectious Diseases in the Combined Infectious Disease Training Program at Harvard Medical School. Upon completion of his training, Dr. Proujansky joined the faculty at the Children’s Hospital of Pittsburgh as Assistant Professor of Pediatrics at University of Pittsburgh School of Medicine.

Dr. Proujansky was appointed Chief Executive of all Nemours Delaware Valley Operations in 2013, including Nemours/Alfred I. duPont Hospital for Children. As Chief Executive of Delaware Valley Operations, he is responsible for all clinical operations at Nemours/Alfred I. duPont Hospital for Children, Nemours duPont Pediatrics and prevention efforts in the Delaware Valley. Dr. Proujansky is based in Wilmington, Del., and reports directly to Nemours President and Chief Executive Officer, David J. Bailey, MD, MBA.

He joined Nemours in 1989 as Chief of the Division of Gastroenterology and Nutrition at the Nemours/Alfred I. duPont Hospital for Children. In 1999, he was named the Chief Executive of the Practice, Nemours duPont Pediatrics (formerly Nemours Children’s Clinic) in Wilmington in the Delaware Valley. From 2000 — 2006 he also served as the Robert L. Brent Professor and Chairman, Department of Pediatrics, and Associate Dean, Jefferson Medical College (Philadelphia).

In 2005, Dr. Proujansky was appointed to the Executive Group as a Vice President of Nemours, and in 2006 became Executive Vice President, Patient Operations and Chief Operating Officer of Nemours responsible for all patient care, research, prevention and education activities.

Independent Director
Saira Ramasastry, M.S. M.Phil.
Saira Ramasastry, M.S.
Ms. Ramasastry has served as Managing Partner of Life Sciences Advisory, LLC, a consulting firm, since 2009. From 1999 to 2009, she was an investment banker with Merrill Lynch & Company, Inc., where she helped establish the biotechnology practice and was responsible for origination of mergers and acquisitions (M&A), strategic and capital markets transactions. Prior to joining Merrill Lynch, she served as a financial analyst in the M&A group at Wasserstein Perella & Co., an investment banking firm. Ms. Ramasastry serves on the boards of directors of Sangamo Therapeutics (NASDAQ: SGMO) and Pain Therapeutics (NASDAQ: PITE) as well she served on the board of directors of Repros Therapeutics (NASDAQ: RPRX), which was acquired by Allergan plc (NYSE: AGN) in February 2018.  Ms. Ramasastry serves on the Industry Advisory Board of the Michael J. Fox Foundation for Parkinson's Research as the lead business advisor for the European Prevention of Alzheimer's Dementia (EPAD) consortium. She received a B.A. in Economics with Honors and Distinction and an M.S. in Management Science and Engineering from Stanford University. She also received an M. Phil. in Management Studies from the University of Cambridge where she is a guest lecturer for the Bioscience Enterprise Programme and serves on the Cambridge Judge Business School Advisory Council.
Independent Director

Copyright West LLC. Minimum 15 minutes delayed.